Back to all studies
🦴
Phase 3
Pain Management
in-person

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Sponsored by Amgen

Compensation

$500–$2,500

Duration

3 months

Location

Nationwide

About this study

The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.

Who can participate

  • • Adults aged 18–99
  • • All genders welcome
  • • Diagnosed with or experiencing sjögren's syndrome
  • • Able to attend in-person clinic visits

What's included

  • • Compensation up to $2,500
  • • All study-related medical care at no cost
  • • Lab work, screenings, and physician consultations
  • • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Apply

Ready to Find a Paid Study?

Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.